S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
S&P 500   4,960.70 (-0.30%)
DOW   38,489.57 (-0.19%)
QQQ   423.61 (-0.87%)
AAPL   181.54 (-0.01%)
MSFT   399.30 (-0.87%)
META   466.61 (-0.98%)
GOOGL   141.99 (+0.62%)
AMZN   167.76 (+0.41%)
TSLA   193.02 (-0.38%)
NVDA   674.10 (-2.94%)
NIO   6.06 (+1.68%)
AMD   162.79 (-1.75%)
BABA   75.81 (+3.65%)
T   16.98 (+0.41%)
F   12.13 (-0.98%)
MU   80.29 (-0.52%)
CGC   3.35 (-5.37%)
GE   148.36 (-0.17%)
DIS   108.02 (-1.30%)
AMC   4.61 (-1.07%)
PFE   27.53 (-0.22%)
PYPL   57.89 (-1.26%)
XOM   104.47 (+1.67%)
NASDAQ:TXMD

TherapeuticsMD (TXMD) Stock Price, News & Analysis

$2.27
0.00 (0.00%)
(As of 12:07 PM ET)
Today's Range
$2.22
$2.27
50-Day Range
$2.23
$2.46
52-Week Range
$1.95
$5.30
Volume
3,690 shs
Average Volume
13,524 shs
Market Capitalization
$24.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TXMD stock logo

About TherapeuticsMD Stock (NASDAQ:TXMD)

TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD Stock Price History

TXMD Stock News Headlines

StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
TherapeuticsMD Inc TXMD
TherapeuticsMD to Consider Strategic Alternatives
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
TheraputicsMD sells products rights for $153 million
See More Headlines
Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
2/21/2024
Next Earnings (Estimated)
4/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TXMD
Previous Symbol
NYSEMKT:TXMD
Employees
1
Year Founded
N/A

Profitability

Net Income
$112 million
Pretax Margin
60.97%

Debt

Sales & Book Value

Annual Sales
$69.96 million
Book Value
$3.73 per share

Miscellaneous

Free Float
10,453,000
Market Cap
$24.02 million
Optionable
Optionable
Beta
1.02
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report














TXMD Stock Analysis - Frequently Asked Questions

Should I buy or sell TherapeuticsMD stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings
or view top-rated stocks.

How have TXMD shares performed in 2024?

TherapeuticsMD's stock was trading at $2.25 on January 1st, 2024. Since then, TXMD shares have decreased by 1.3% and is now trading at $2.22.
View the best growth stocks for 2024 here
.

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 54,900 shares, a drop of 57.7% from the January 15th total of 129,800 shares. Based on an average daily volume of 21,800 shares, the short-interest ratio is currently 2.5 days. Currently, 0.5% of the shares of the company are short sold.
View TherapeuticsMD's Short Interest
.

When is TherapeuticsMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, April 5th 2024.
View our TXMD earnings forecast
.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.17. The business had revenue of $0.44 million for the quarter. TherapeuticsMD had a trailing twelve-month return on equity of 133.83% and a net margin of 47.29%.

When did TherapeuticsMD's stock split?

TherapeuticsMD's stock reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by many different institutional and retail investors. Top institutional investors include ADAR1 Capital Management LLC (2.57%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Edward Borkowski, Gail K Naughton, James Darecca, Marlan D Walker, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Rubric Capital Management Lp, Tommy G Thompson and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TXMD) was last updated on 2/21/2024 by MarketBeat.com Staff